Inhibition of IL-6 family cytokines by SOCS3 - PubMed (original) (raw)
Review
Inhibition of IL-6 family cytokines by SOCS3
Jeffrey J Babon et al. Semin Immunol. 2014 Feb.
Abstract
IL-6 a multi-functional cytokine with important effects in both inflammation and haematopoiesis. SOCS3 is the primary inhibitor of IL-6 signalling, interacting with gp130, the common shared chain of the IL-6 family of cytokines, and JAK1, JAK2 and TYK2 to control both the duration of signalling and the biological response. Recent biochemical and structural studies have shown SOCS3 binds to only these three JAKs, all of which are associated with IL-6 signalling, and not JAK3. This specificity is determined by a three residue "GQM" motif in the kinase domain of JAK1, JAK2 and TYK2. SOCS3 binds to JAK and gp130 simultaneously, and inhibits JAK activity in an ATP-independent manner by partially occluding the kinase's substrate binding groove with its kinase inhibitory region. We therefore propose a model in which each of gp130, JAK and SOCS3 are directly bound to the other two, allowing SOCS3 to inhibit IL6 signalling with high potency and specificity.
Keywords: Cytokine signalling; IL-6; JAK/STAT; Janus Kinases; SOCS.
Crown Copyright © 2014. Published by Elsevier Ltd. All rights reserved.
Figures
Figure 1. IL-6 signalling and its inhibition
Schematic diagram illustrating activation (left) of the JAK/STAT signalling cascade in response to IL-6 and the termination of signalling (right) catalysed by SOCS3. IL-6 signals via a cell-surface receptor that consists of a 2:2 gp130(blue):IL-6Rα (orange) tetramer. Interaction between the cytokine and its receptor induces the autoactivation (in trans) of Janus Kinases (JAKs,: JAK1, JAK2, TYK2; shown in beige) bound to the cytoplasmic domain of gp130. Activated JAK then phosphorylates five tyrosines within gp130cyt. Four of these phosphotyrosines recruit STAT3 or STAT1/STAT3 which are then themselves phosphorylated, and thereby activated, by JAK, translocate to the nucleus and begin inducing the transcription of IL-6-responsive genes. STATs also upregulate the transcription of SOCS3 (red) which binds to the fifth phosphotyrosine in gp130cyt (pY759) and shuts down the JAK/STAT signalling cascade by binding to JAK and directly inhibiting its catalytic activity, forming a negative feedback loop. This phosphotyrosine also recruits SHP-2, which leads to activation of the MAPK/ERK and PI3K pathways (not shown here) and therefore SOCS3, which competes for this site, is also capable of inhibiting those signalling cascades. Signalling and inhibition is symmetric with respect to both gp130 chains and is shown here divided into left and right for ease of illustration. The structures shown are those solved and/or modelled for components of the signalling cascade, Note that the pseudokinase and SH2-like domains of JAK are omitted for clarity in this figure.
Figure 2. SOCS3 inhibits the duration of IL-6 signalling by direct inhibition of JAK1, JAK2 and TYK2 but not JAK3
(A) Schematic diagram showing the effect of SOCS3 on STAT1 and STAT3 activation post IL-6 stimulation. Shown is a representation of the data from[46] (B). The structure of SOCS3 (PDB 4GL9) with an explanation of the major functional motifs shown as a schematic below. Note that the PEST motif is absent from the structure and that the SOCS box has been modelled based on the structure of the SOCS2 SOCS box (PDB 2C9W). (C) SOCS3 (red) binds the kinase domains of JAK1, JAK2 and TYK2 and inhibits its catalytic activity by blocking the substrate binding site with its kinase inhibitory region (black). Note that SOCS3 remains bound to gp130 (blue) whilst in complex with JAK (beige) and that ATP binding is unaffected.
Figure 3
SOCS3 inhibits IL-6 family signalling by targeting a gp130:JAK dimer.
Similar articles
- Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity.
Babon JJ, Kershaw NJ, Murphy JM, Varghese LN, Laktyushin A, Young SN, Lucet IS, Norton RS, Nicola NA. Babon JJ, et al. Immunity. 2012 Feb 24;36(2):239-50. doi: 10.1016/j.immuni.2011.12.015. Immunity. 2012. PMID: 22342841 Free PMC article. - The biology and mechanism of action of suppressor of cytokine signaling 3.
Babon JJ, Nicola NA. Babon JJ, et al. Growth Factors. 2012 Aug;30(4):207-19. doi: 10.3109/08977194.2012.687375. Epub 2012 May 11. Growth Factors. 2012. PMID: 22574771 Free PMC article. Review. - SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition.
Kershaw NJ, Murphy JM, Liau NP, Varghese LN, Laktyushin A, Whitlock EL, Lucet IS, Nicola NA, Babon JJ. Kershaw NJ, et al. Nat Struct Mol Biol. 2013 Apr;20(4):469-76. doi: 10.1038/nsmb.2519. Epub 2013 Mar 3. Nat Struct Mol Biol. 2013. PMID: 23454976 Free PMC article. - Key role of suppressor of cytokine signaling 3 in regulating gp130 cytokine-induced signaling and limiting chondrocyte responses during murine inflammatory arthritis.
Liu X, Croker BA, Campbell IK, Gauci SJ, Alexander WS, Tonkin BA, Walsh NC, Linossi EM, Nicholson SE, Lawlor KE, Wicks IP. Liu X, et al. Arthritis Rheumatol. 2014 Sep;66(9):2391-402. doi: 10.1002/art.38701. Arthritis Rheumatol. 2014. PMID: 24839265 - Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.
Heinrich PC, Behrmann I, Müller-Newen G, Schaper F, Graeve L. Heinrich PC, et al. Biochem J. 1998 Sep 1;334 ( Pt 2)(Pt 2):297-314. doi: 10.1042/bj3340297. Biochem J. 1998. PMID: 9716487 Free PMC article. Review.
Cited by
- Endothelial SOCS3 maintains homeostasis and promotes survival in endotoxemic mice.
Martino N, Ramos RB, Lu S, Leyden K, Tomaszek L, Sadhu S, Fredman G, Jaitovich A, Vincent PA, Adam AP. Martino N, et al. JCI Insight. 2021 Jul 22;6(14):e147280. doi: 10.1172/jci.insight.147280. JCI Insight. 2021. PMID: 34138760 Free PMC article. - Absence of GP130 cytokine receptor signaling causes extended Stüve-Wiedemann syndrome.
Chen YH, Grigelioniene G, Newton PT, Gullander J, Elfving M, Hammarsjö A, Batkovskyte D, Alsaif HS, Kurdi WIY, Abdulwahab F, Shanmugasundaram V, Devey L, Bacrot S, Brodszki J, Huber C, Hamel B, Gisselsson D, Papadogiannakis N, Jedrycha K, Gürtl-Lackner B, Chagin AS, Nishimura G, Aschenbrenner D, Alkuraya FS, Laurence A, Cormier-Daire V, Uhlig HH. Chen YH, et al. J Exp Med. 2020 Mar 2;217(3):e20191306. doi: 10.1084/jem.20191306. J Exp Med. 2020. PMID: 31914175 Free PMC article. - Murine astrocytes produce IL-24 and are susceptible to the immunosuppressive effects of this cytokine.
Burmeister AR, Johnson MB, Yaemmongkol JJ, Marriott I. Burmeister AR, et al. J Neuroinflammation. 2019 Mar 2;16(1):55. doi: 10.1186/s12974-019-1444-1. J Neuroinflammation. 2019. PMID: 30825881 Free PMC article. - Interleukin-6 _Trans_-Signaling Pathway Promotes Immunosuppressive Myeloid-Derived Suppressor Cells via Suppression of Suppressor of Cytokine Signaling 3 in Breast Cancer.
Jiang M, Chen J, Zhang W, Zhang R, Ye Y, Liu P, Yu W, Wei F, Ren X, Yu J. Jiang M, et al. Front Immunol. 2017 Dec 15;8:1840. doi: 10.3389/fimmu.2017.01840. eCollection 2017. Front Immunol. 2017. PMID: 29326716 Free PMC article. - Involvement of the IL-6 Signaling Pathway in the Anti-Anhedonic Effect of the Antidepressant Agomelatine in the Chronic Mild Stress Model of Depression.
Rossetti AC, Paladini MS, Brüning CA, Spero V, Cattaneo MG, Racagni G, Papp M, Riva MA, Molteni R. Rossetti AC, et al. Int J Mol Sci. 2022 Oct 18;23(20):12453. doi: 10.3390/ijms232012453. Int J Mol Sci. 2022. PMID: 36293308 Free PMC article.
References
- Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813:878–88. - PubMed
- Nicola NA, editor. Guidebook to Cytokines and Their Receptors. Oxford University Press; 1994.
- Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol. 1997;15:797–819. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous